Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3742 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

UK biotech industry receives government support

Representatives from AstraZeneca, Pfizer, GlaxoSmithkline, Amgen, and other firms were at Amgen’s new European HQ in Uxbridge to discuss how to maintain the UK’s competitive edge in the

Abbott launches Factive in Canada

Oscient granted the commercialization rights for Factive to Abbott Canada in August of last year. Oscient received a modest milestone payment from Abbott Canada related to the launch.

Idenix hepatitis B therapy authorized in China

Hepatitis B remains a significant global health care concern, particularly in China where it affects more than 100 million people. Sebivo, generic name telbivudine, is expected to be

New drug halts the progress of kidney cancer

Usual treatment for kidney cancer of a metastatic nature has been based solely on immunotherapy. But treatment with immunotherapy has not shown clearly positive results in many patients.